此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Preventing Dyspnea During Speech in Older Speakers

2022年6月24日 更新者:Maude Desjardins、University of Delaware

Self-Regulated Airflow Management in Daily Communicative Activities to Prevent Dyspnea During Speech in Older Speakers

Due to various comorbidities affecting the respiratory system, older speakers are at risk of experiencing breathing discomfort (dyspnea) during high-demand vocal activities such as singing, loud speaking, and speaking while exercising. Dyspnea during speech can promote avoidance of certain situations involving voice production, thus leading to vocal deconditioning and decreased quality of life. The goal of this pilot study is to test the feasibility and acceptability of a 4-week remote group intervention targeting phonatory dyspnea, and to gather preliminary efficacy data.

Participants will receive an intervention including a 2-week socialization phase (control condition) and a 4-week speech breathing intervention phase (experimental condition). Both phases will be delivered remotely and in a group setting (10 participants per group).

研究概览

研究类型

介入性

注册 (实际的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Delaware
      • Newark、Delaware、美国、19713
        • University of Delaware

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • sign the informed consent form
  • report dyspnea in at least one of the items of the University of Cincinnati Dyspnea Questionnaire referring to speech
  • be available during the dates of the scheduled group interventions
  • be aged 50 years or older

Exclusion Criteria:

  • do not have access to a computer and internet connection
  • present with a known voice pathology (other than age-related vocal fold atrophy) and/or are receiving speech therapy at the time of the study
  • have a known neurodegenerative disease affecting speech/voice
  • are a current smoker
  • are receiving pulmonary rehabilitation at the time of the study or are starting a new medication regimen for a respiratory disease at the time of study onset;
  • have a hearing loss that is not adequately managed, as judged by the Principal Investigator (PI)
  • have professional vocal training [amateur choir singers will not be excluded]
  • cannot provide informed consent or easily follow instructions
  • have any other condition that precludes them from participating in the behavioral interventions, as judged by the PI.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:All participants
This is a single-arm trial. All participants will receive (1) a control condition (socialization phase, 2 weeks) and (2) an intervention condition (speech breathing intervention, 4 weeks). Group sessions will take place once a week, and participants will be instructed to practice their exercises every day at home during the study duration.
Control condition: does not involve speech-related exercises
Experimental condition: involves speech-related exercises

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in reported dyspnea
大体时间:Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
Participant self-ratings of dyspnea on the University of Cincinnati Dyspnea Questionnaire. This questionnaire contains 30 items scored on a Likert scale ranging from 1 (not at all short of breath) to 5 (always short of breath or cannot do). A higher scores indicates greater shortness of breath and therefore greater handicap.
Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
Change in reported voice handicap
大体时间:Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
Participant self-ratings of voice handicap on the Voice Handicap Index-10. The Voice Handicap Index-10 is an ordinal scale that measures the degree of handicap a person experiences because of their voice disorder. Each item is scored on a Likert scale ranging from 0 to 4. The minimum score is 0 and the maximal score 40. A higher score indicates a greater perceived voice handicap.
Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.

次要结果测量

结果测量
措施说明
大体时间
Change in reported self-efficacy
大体时间:Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
Participant self-ratings of self-efficacy for managing their symptoms, using the Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy Questionnaire - Managing Symptoms. This questionnaire contains 28 items, each scored on a Likert scale ranging from 1 (I am not at all confident) to 5 (I am very confident). A higher score indicates a greater self-efficacy.
Assessed at baseline, after the 2-week control condition, and after the 4-week experimental condition.
Acceptability of the intervention
大体时间:Assessed after the 4-week experimental condition, at the end of the study period.
Participants' perceived acceptability of the intervention using the Acceptability of Intervention Measure. This questionnaire contains 5 items scored on a Likert scale ranging from 1 (completely disagree) to 5 (completely agree). A higher score indicates a greater acceptability.
Assessed after the 4-week experimental condition, at the end of the study period.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年9月15日

初级完成 (实际的)

2022年3月10日

研究完成 (实际的)

2022年3月10日

研究注册日期

首次提交

2021年8月29日

首先提交符合 QC 标准的

2021年8月29日

首次发布 (实际的)

2021年9月1日

研究记录更新

最后更新发布 (实际的)

2022年6月29日

上次提交的符合 QC 标准的更新

2022年6月24日

最后验证

2022年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅